Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Colorectal Neoplasms 4Pancreatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Malnutrition 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Biliary Tract Neoplasms 2Peptic Ulcer 1Osteoporosis 1Neoplasms 1Neoplasm Metastasis 1Myocardial Ischemia 1Liver Neoplasms 1Inflammatory Bowel Diseases 1Hyperphagia 1Hepatitis C, Chronic 1Heart Diseases 1Fibrosis 1Duodenal Neoplasms 1Coronary Disease 1Clinical Stage III Esophageal Adenocarcinoma AJCC v8 1Cardiovascular Diseases 1Bone Diseases 1Anus Neoplasms 1Abdominal Neoplasms 1

Interventions

Ribavirin 4ledipasvir 2Sofosbuvir 2sofosbuvir-velpatasvir drug combination 1peginterferon alfa-2a 1ledipasvir, sofosbuvir drug combination 1daclatasvir 1Viusid 1Simeprevir 1Metformin 1Introns 1Dietary Supplements 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatitis C, Chronic × Dietary Supplements × Gastrointestinal × Clear all
NCT00502086 2011-02-11

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Catalysis SL

Phase 3 Completed
100 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡